BioAge Labs, Inc.
NASDAQ:BIOABiotechnology
+$0.47 today
- Market cap
- $179.59M
- Beta
- 0.95
- P/E (TTM)
- -9.7
- EPS (TTM)
- -$2.12
Volume 0.64M
Average 0.46M
BIOA Total Non-current Liabilities
All obligations due after more than one year.
BioAge Labs, Inc.NASDAQ: BIOA
Total Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total non-current liabilities falls 61.0% from a year ago
Total non-current liabilities stood at $2.71M at the end of Q1 FY2026, down 61.0% from a year earlier and up 0.2% from the prior quarter. Over 3 fiscal years it compounded at -72.9% a year.
Context
- Total non-current liabilities amounted to 0.7% of total assets at the end of Q1 FY2026, down 1.3 pp from a year earlier.
- Total non-current liabilities increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total non-current liabilities keeps falling in the next quarterly balance sheet after a -61.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 2.7M USD
- Year-over-year change
- -63.2%
- 3-year CAGR
- -72.9%
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.7M | -63.2% |
| FY2024 | 2024-12-31 | 7.33M | -94.8% |
| FY2023 | 2023-12-31 | 141.15M | +4.5% |
| FY2022 | 2022-12-31 | 135.13M | — |
Total Non-current Liabilities vs competitors
How BIOA compares with its peers on the latest reported figures
- Peers report in different currencies, so total non-current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -61.0% is the 6th highest of 9, against a peer median of -22.1%.
- Total non-current liabilities amounts to 0.7% of total assets for BIOA, versus a peer median of 23.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | CA$262.7M CAD | -21.8% | -25.2% | 23.5% | |
| Dec 2025 | $222.81M USD | — | — | 96.0% | |
| Mar 2026 | $105.15M USD | -17.9% | +6.5% | 70.4% | |
| Mar 2026 | $88.75M USD | -4.1% | -3.5% | 22.4% | |
| Mar 2026 | $82.75M USD | -22.3% | +11.9% | 74.8% | |
| Mar 2026 | $26.84M USD | -5.3% | -13.1% | 27.2% | |
| Mar 2026 | CA$22.38M CAD | -83.1% | -48.8% | 3.7% | |
| Mar 2026 | $3.33M USD | -65.3% | -0.9% | 2.3% | |
BIOABioAge Labs, Inc. | Mar 2026 | $2.71M USD | -61.0% | -72.9% | 0.7% |
| Mar 2026 | $0 USD | -100.0% | — | 0.0% | |
| Peer median (excluding BIOA) | — | -22.1% | -3.5% | 23.5% | |
Competitors are the stored peer set for BIOA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
BioAge Labs, Inc.
NASDAQ:BIOA
Intrinsic Alpha fair value
Locked
Current Price
$4.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.